CSPC Pharmaceutical Group Limited
(Formerly known as China Pharmaceutical Group Limited)
(Incorporated in Hong Kong under the Companies Ordinance)

Announcements & Notices       

2023-December-1	VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA (in PDF)
2023-November-30	VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-November-30	QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 (in PDF)
2023-November-29	POLL RESULTS OF THE FURTHER ADJOURNED EGM HELD ON 29 NOVEMBER 2023 (in PDF)
2023-November-27	VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-November-20	DATE OF BOARD MEETING (in PDF)
2023-November-17	VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR TREATMENT OF ACUTE ISCHEMIC STROKE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
2023-November-13	NOTICE OF FURTHER ADJOURNED EGM (in PDF)
2023-November-10	FURTHER ADJOURNMENT OF EGM (in PDF)
2023-November-6	VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA (in PDF)
2023-November-3	ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING NOTICE OF ADJOURNED EXTRAORDINARY GENERAL MEETING (in PDF)
2023-November-3	VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-November-1	VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-October-30	VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-October-25	VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
2023-October-24	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 (in PDF)
2023-October-9	NOTICE OF EXTRAORDINARY GENERAL MEETING (in PDF)
2023-October-9	DESPATCH OF CIRCULAR IN RELATION TO (1) GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND (2) APPLICATION FOR WHITEWASH WAIVER (in PDF)
2023-September-22	DELAY IN DESPATCH OF CIRCULAR (in PDF)
2023-September-15	VOLUNTARY ANNOUNCEMENT - IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-September-12	APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER (in PDF)
2023-September-6	(REVISED) VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA (in PDF)
2023-September-6	VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA (in PDF)
2023-September-4	GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND APPLICATION FOR WHITEWASH WAIVER (in PDF)
2023-August-29	VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-August-28	2023 INTERIM DIVIDEND (in PDF)
2023-August-24	VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-August-23	2023 INTERIM DIVIDEND (in PDF)
2023-August-23	2023 INTERIM RESULTS (in PDF)
2023-August-21	VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION AGREEMENTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE (AI) IN INNOVATIVE DRUG RESEARCH AND DEVELOPMENT (in PDF)
2023-August-17	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2023 (in PDF)
2023-August-17	VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
2023-August-11	DATE OF BOARD MEETING (in PDF)
2023-July-4	VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-July-3	VOLUNTARY ANNOUNCEMENT - RABEPRAZOLE SODIUM ENTERIC-COATED TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-June-29	VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION OF BATOCLIMAB (HBM9161) ACCEPTED BY THE NMPA (in PDF)
2023-June-29	VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP WITH PFIZER TO LAUNCH LOCAL BRAND OF ORAL ANTIVIRAL TREATMENT FOR COVID-19 IN CHINA (in PDF)
2023-June-26	VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION (in PDF)
2023-June-26	VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-June-26	VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
2023-June-23	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2023-June-21	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2023-June-19	VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
2023-June-14	VOLUNTARY ANNOUNCEMENT - PALIPERIDONE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-June-14	VOLUNTARY ANNOUNCEMENT - MIRABEGRON EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-June-12	VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-June-12	VOLUNTARY ANNOUNCEMENT - CPO301 WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA (in PDF)
2023-June-8	VOLUNTARY ANNOUNCEMENT - CPO301 OBTAINS CLINICAL TRIAL APPROVAL IN CANADA (in PDF)
2023-May-31	POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 31 MAY 2023 (in PDF)
2023-May-30	VOLUNTARY ANNOUNCEMENT - CLINICAL DATA OF ALMB-0168 FOR THE TREATMENT OF OSTEOSARCOMA TO BE PRESENTED AT THE 2023 ASCO ANNUAL MEETING (in PDF)
2023-May-30	GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY (in PDF)
2023-May-25	QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2023 (in PDF)
2023-May-15	DATE OF BOARD MEETING (in PDF)
2023-April-26	VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS (in PDF)
2023-April-26	NOTICE OF ANNUAL GENERAL MEETING (in PDF)
2023-April-25	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2023 (in PDF)
2023-April-20	VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-April-2	VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE CPO301 OBTAINS CLINIAL TRIAL APPROVAL IN THE U.S. (in PDF)
2023-March-27	VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
2023-March-22	CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER (in PDF)
2023-March-22	ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022 (in PDF)
2023-March-22	VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA (in PDF)
2023-March-16	INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022 (in PDF)
2023-March-10	VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION (in PDF)
2023-March-10	DATE OF BOARD MEETING (in PDF)
2023-March-2	VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA (in PDF)
2023-February-23	REMUNERATION COMMITTEE - TERMS OF REFERENCE (in PDF)
2023-February-23	NOMINATION COMMITTEE - TERMS OF REFERENCE (in PDF)
2023-February-16	VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA (in PDF)
2023-February-13	VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6002 WITH CORBUS PHARMACEUTICALS (in PDF)
2023-January-19	VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-January-9	VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-January-5	VOLUNTARY ANNOUNCEMENT - MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2023-January-4	VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PRMT5 INHIBITOR SYH2045 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
2022	2022 Announcements & Notices
2021	2021 Announcements & Notices
2020	2020 Announcements & Notices
2019	2019 Announcements & Notices
2018	2018 Announcements & Notices
2017	2017 Announcements & Notices
2016	2016 Announcements & Notices
2015	2015 Announcements & Notices
2014	2014 Announcements & Notices
2013	2013 Announcements & Notices
2012	2012 Announcements & Notices
2011	2011 Announcements & Notices
2010	2010 Announcements & Notices
2009	2009 Announcements & Notices
2008	2008 Announcements & Notices
2007	2007 Announcements & Notices
2006	2006 Announcements & Notices